|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tsai JY and Safran H: Status of treatment
for advanced gastric carcinoma. Curr Oncol Rep. 5:210–218. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Power DG, Kelsen DP and Shah MA: Advanced
gastric cancer slow but steady progress. Cancer Treat Rev.
36:384–392. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wagner AD, Unverzagt S, Grothe W, Kleber
G, Grothey A, Haerting J and Fleig WE: Chemotherapy for advanced
gastric cancer. Cochrane Database Syst Rev. CD0040642010.PubMed/NCBI
|
|
5
|
Sakuramoto S, Sasako M, Yamaguchi T,
Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi
Y, Imamura H, et al: ACTS-GC Group: Adjuvant chemotherapy for
gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med.
357:1810–1820. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Koizumi W, Narahara H, Hara T, Takagane A,
Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama
W, et al: S-1 plus cisplatin versus S-1 alone for first-line
treatment of advanced gastric cancer (SPIRITS trial): A phase III
trial. Lancet Oncol. 9:215–221. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Boku N, Yamamoto S, Fukuda H, Shirao K,
Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, et
al: Fluorouracil versus combination of irinotecan plus cisplatin
versus S-1 in metastatic gastric cancer: A randomised phase 3
study. Lancet Oncol. 10:1063–1069. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sato Y, Takayama T, Sagawa T, Takahashi Y,
Ohnuma H, Okubo S, Shintani N, Tanaka S, Kida M, Sato Y, et al:
Phase II study of S-1, docetaxel and cisplatin combination
chemotherapy in patients with unresectable metastatic gastric
cancer. Cancer Chemother Pharmacol. 66:721–728. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yamaguchi H, Kitayama J, Ishigami H, Emoto
S, Yamashita H and Watanabe T: A phase II trial of intravenous and
intraperitoneal paclitaxel combined with S-1 for treatment of
gastric cancer with macroscopic peritoneal metastasis. Cancer.
119:3354–3358. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bang YJ, Kim YW, Yang HK, Chung HC, Park
YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, et al: Adjuvant
capecitabine and oxaliplatin for gastric cancer after D2
gastrectomy (CLASSIC): A phase III open-label randomised controlled
trial. Lancet. 379:315–321. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Oki E, Emi Y, Kusumoto T, Sakaguchi Y,
Yamamoto M, Sadanaga N, Shimokawa M, Yamanaka T, Saeki H, Morita M,
et al: Phase II study of docetaxel and S-1 (DS) as neoadjuvant
chemotherapy for clinical stage III resectable gastric cancer. Ann
Surg Oncol. 21:2340–2346. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bang YJ, Van Cutsem E, Feyereislova A,
Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T,
et al: Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric
or gastro-oesophageal junction cancer (ToGA): A phase 3,
open-label, randomized controlled trial. Lancet. 376:687–697. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Thuss-Patience PC, Kretzschmar A, Bichev
D, Deist T, Hinke A, Breithaupt K, Dogan Y, Gebauer B, Schumacher G
and Reichardt P: Survival advantage for irinotecan versus best
supportive care as second-line chemotherapy in gastric cancer-a
randomised phase III study of the Arbeitsgemeinschaft
Internistische Onkologie (AIO). Eur J Cancer. 47:2306–2314. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kang JH, Lee SI, Lim do H, Park KW, Oh SY,
Kwon HC, Hwang IG, Lee SC, Nam E, Shin DB, et al: Salvage
chemotherapy for pretreated gastric cancer: A randomized phase III
trial comparing chemotherapy plus best supportive care with best
supportive care alone. J Clin Oncol. 30:1513–1518. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim HS, Kim HJ, Kim SY, Kim TY, Lee KW,
Baek SK, Kim TY, Ryu MH, Nam BH and Zang DY: Second-line
chemotherapy versus supportive cancer treatment in advanced gastric
cancer: A meta-analysis. Ann Oncol. 24:2850–2854. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shimizu T and Saijo N: Common toxicity
criteria: Version 2.0, an improved reference for grading the
adverse reaction of cancer treatment. Nihon Rinsho. 61:937–942.
2003.PubMed/NCBI
|
|
17
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Glimelius B, Hoffman K, Haglund U, Nyrén O
and Sjödén PO: Initial or delayed chemotherapy with best supportive
care in advanced gastric cancer. Ann Oncol. 5:189–190. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pyrhönen S, Kuitunen T, Nyandoto P and
Kouri M: Randomised comparison of fluorouracil, epidoxorubicin and
methotrexate (FEMTX) plus supportive care with supportive care
alone in patients with non-resectable gastric cancer. Br J Cancer.
71:587–591. 1995. View Article : Google Scholar : PubMed/NCBI
|
